These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 7687519)

  • 1. Systemic therapy of prostate cancer. New concepts from prostate cancer tumor biology.
    Hsieh WS; Simons JW
    Cancer Treat Rev; 1993 Jul; 19(3):229-60. PubMed ID: 7687519
    [No Abstract]   [Full Text] [Related]  

  • 2. Stanford experience with chemotherapy for metastatic prostate cancer.
    Torti FM; Reese J; Freiha F
    Prog Clin Biol Res; 1990; 350():171-85. PubMed ID: 1696740
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant systemic therapy of prostate cancer.
    Raghavan D
    Semin Oncol; 1995 Dec; 22(6):633-40. PubMed ID: 8539638
    [No Abstract]   [Full Text] [Related]  

  • 4. Adjuvant chemotherapy for T3 prostate cancer: not ready for prime time.
    Carducci MA
    Urology; 2000 Feb; 55(2):157-60. PubMed ID: 10688070
    [No Abstract]   [Full Text] [Related]  

  • 5. Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed!
    Collette L; Buyse M; Burzykowski T
    J Clin Oncol; 2007 Dec; 25(35):5673-4; author reply 5674. PubMed ID: 18065747
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of prostate cancer].
    Imre R
    Orv Hetil; 2005 Aug; 146(35):1839-42. PubMed ID: 16187544
    [No Abstract]   [Full Text] [Related]  

  • 7. Serial monitoring of patients with prostate cancer treated with anti-androgen therapy.
    Stamey TA
    Cancer; 1992 Nov; 70(9):2378. PubMed ID: 1382833
    [No Abstract]   [Full Text] [Related]  

  • 8. Overview consensus statement. Fifth International Conference on Neoadjuvant Hormonal Therapy for Prostate Cancer.
    Garnick MB; Fair WR; Bostwick D; Debruyne F; Fourcroy J; Grignon D; Porterfield H; Sufrin G; Thrasher B; Hart C
    Mol Urol; 2000; 4(3):89-92. PubMed ID: 11184767
    [No Abstract]   [Full Text] [Related]  

  • 9. Do we really need new trials on fulvestrant in prostate cancer?
    Féchon A; Droz JP
    Onkologie; 2010; 33(1-2):12-3. PubMed ID: 20164656
    [No Abstract]   [Full Text] [Related]  

  • 10. [Determination of tumor marker doubling time in the patients with prostate cancer relapsed from endocrine therapy].
    Akimoto S; Masai M; Kitagawa N; Nakamura T; Shimazaki J
    Nihon Hinyokika Gakkai Zasshi; 1993 Mar; 84(3):450-6. PubMed ID: 7685840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnosis and treatment of early prostate cancer].
    Kaprin AD; Khalil Farzat M; Gafanov RA; Kostin AA
    Vopr Onkol; 2009; 55(3):382-5. PubMed ID: 19670743
    [No Abstract]   [Full Text] [Related]  

  • 12. [Adjuvant treatment of prostatic carcinoma after primary therapy. The "Early Prostate Cancer" Program].
    Mansueto G; Longo F
    Recenti Prog Med; 2002 Mar; 93(3):175-8. PubMed ID: 11942169
    [No Abstract]   [Full Text] [Related]  

  • 13. Systemic treatment and new developments in advanced prostate cancer.
    Sternberg CN
    Eur J Cancer; 2001 Oct; 37 Suppl 7():S147-57. PubMed ID: 11887986
    [No Abstract]   [Full Text] [Related]  

  • 14. Prostate-specific antigen: concepts for staging prostate cancer and monitoring response to therapy.
    Ruckle HC; Klee GG; Oesterling JE
    Mayo Clin Proc; 1994 Jan; 69(1):69-79. PubMed ID: 7505870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival.
    Small EJ; McMillan A; Meyer M; Chen L; Slichenmyer WJ; Lenehan PF; Eisenberger M
    J Clin Oncol; 2001 Mar; 19(5):1304-11. PubMed ID: 11230472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction by the Guest Editor: The Rapidly Evolving Treatment Landscape of Prostate Cancer-The Convergence of Treatment Paradigms of Localized and Metastatic Diseases.
    Spratt DE
    Cancer J; 2020; 26(1):1. PubMed ID: 31977378
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase.
    Akimoto S; Inomiya H; Akakura K; Shimazaki J; Ito H
    Jpn J Clin Oncol; 1997 Aug; 27(4):258-62. PubMed ID: 9379515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen.
    Ornstein DK; Pruthi RS
    Expert Opin Pharmacother; 2000 Dec; 1(7):1399-411. PubMed ID: 11249473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Utility of prostate-specific antigen in pleural fluid for the diagnosis of metastatic effusion secondary to prostate cancer].
    Sánchez Merino JM; Quintana González JI; Toribio Sánchez CM; Gómez Cisneros SC; Parra Muntaner L; García Alonso J
    Actas Urol Esp; 2002; 26(7):513-4. PubMed ID: 12224436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Adjuvant therapy of locally advanced prostate carcinoma with ibandronate].
    Lindenmeir T; Ulrich M; Rau O; Reiher F; Allhoff EP
    Urologe A; 2007 Sep; 46(9):1287. PubMed ID: 17694295
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.